SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Businessmans hand holding a red globe with the map of China, symbolizing international business, trade, global markets, global influence, economics, or Chinese business ventures
China
Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive
Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is only scratching at the surface of partnership-ready biotechs in the region.
August 6, 2025
 · 
7 min read
 · 
Leslie Zhen Liang
Venture capital
Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future
While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and venture funds to uncover cutting-edge scientific trends, determine their future focus points and even carve out a niche in an emerging geographical hotspot.
August 6, 2025
 · 
5 min read
 · 
Heather McKenzie
Phone headset in hands flat vector illustration. Phone as symbol of connection with customer, support or feedback. Hotline, service, media, network, help concept
Earnings
Pfizer CEO in Touch With President Over Most Favored Nation Drug Pricing
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other pharmaceutical companies to lower drug prices or face consequences.
August 5, 2025
 · 
3 min read
 · 
Annalee Armstrong
Sep 21, 2020 Brisbane / CA / USA - BioMarin headquarters in Silicon Valley; BioMarin Pharmaceutical Inc. is an American biotechnology company
Rare diseases
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Set of diferent colored scissors vector. Scissor icon in cartoon and flat style. Open cutting or nippers. Vector illustration.
Job Trends
July Layoffs Skyrocket 487% YOY With Merck Cuts
The number of biopharma professionals let go has increased year over year for three straight months. In July, as many as 8,000 people lost or were projected to lose their jobs, due largely to news that Merck projects to cut roughly 6,000 employees as part of a multiyear process.
August 5, 2025
 · 
4 min read
 · 
Angela Gabriel
©Vertex Pharmaceuticals Incorporated. All Rights Reserved.
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
August 5, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Human head with puzzle pieces and doodles vector illustration. Human brain lacking a piece of puzzle. Concept of brain function, memory loss, disorder, dementia. Abstract human head profile
Neuroscience
Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial
Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that of its closest competitors.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Start of negative growth trend. Worsening forecast. Cessation of rise inertia, not enough power energy. The risk of recession and sliding into a crisis
Regulatory
Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
A stack of white envelopes with a red envelope on top. Blue background with copy space.
Regulatory
Scientists Behind Trial of Replimune’s Tumor Destroyer Protest FDA’s Rejection
In an open letter, 22 experts who designed and ran Replimune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined in the complete response letter for the melanoma candidate RP1.
August 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS